Sort by
Refine Your Search
-
Listed
-
Country
-
Field
-
in screening informatics, biological data analysis, and drug discovery workflows to support the development and delivery of screening and pharmacology programmes within the ARUK UCL Drug Discovery
-
be with UCL colleagues, you will be expected to develop positive working relationships with ICGNMD researchers across the UK and internationally, therefore strong communication and data reporting
-
translational environment of the UCL Institute of Neurology, the ARUK UDDI is uniquely placed to find novel targets, rapidly validate identified novel targets and mechanisms, establish screens and progress
-
The UCL Cancer Institute is the hub for cancer research at University College London (UCL), one of the world's leading universities (www.ucl.ac.uk/cancer ). We are looking for a talented and
-
-at-ucl/search-ucl-jobs ) and search using vacancy reference B02-10209. To apply, please upload a current CV, complete the online application form, and use the supporting statement section or upload a cover
-
About us The UCL Laboratory for Molecular Cell Biology (LMCB, http:/www.ucl.ac.uk/lmcb) is an internationally renowned, multidisciplinary, molecular and cell biology department, located in the heart
-
short-read, long-read, and transcriptome data. There is also the potential to develop and publish novel analytical approaches. This is a unique opportunity to work alongside clinical experts
-
person specifications of the role as well as your responsibilities and benefits are included in the following. Ample networking and collaboration opportunities within UCL including Chemistry, Physics
-
developing skills and understanding of data linkage. What we offer Visit https://www.ucl.ac.uk/work-at-ucl/reward-and-benefits to find out more. Our commitm ent to Equality, Diversity and Inclusion As
-
. The UCL GOS ICH, together with its clinical partner Great Ormond Street Hospital for Children, forms the largest concentration of children’s health research outside North America. The 2024-29 GOS ICH